Cassava Sciences Inc vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $45.09M), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $33.55. The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | FNGU | |
|---|---|---|
Market Cap | $45.09M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $36.15 |
52-Week Low | $0.87 | $13.73 |
Enterprise Value | -$37.60M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $32.19, down 4.48% on the day, with recent volatility highlighted by a 16% single-session drop on June 5, 2026. Technical indicators show a bullish moving average signal but overbought RSI levels, with key support at $32 and resistance at $34. The product's inherent leverage amplifies both gains and losses, as seen in recent performance gaps versus the underlying index.
The outlook for FNGU is highly speculative, driven by leveraged exposure to mega-cap tech stocks. Investment opportunity lies in magnified upside during strong bull markets, but risks are severe, including decay from daily rebalancing and extreme volatility. Investors face potential rapid capital erosion in downturns, as evidenced by recent sharp declines.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →